The involvement of bioactive SLs in AML is a rapidly expanding field, with initial studies exploring SPHK1 as a therapeutic target [137,138,139] and showing decreased ceramide levels associated with increased GCS and SMS activities as indicative of chemoresistance [140]. Here, UGCG is linked to acute myeloid leukemia.